Detalles de la búsqueda
1.
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
BMC Cancer
; 20(1): 356, 2020 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32345265
2.
Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer.
Future Oncol
; 16(22): 1575-1584, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32495656
3.
Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer.
Future Oncol
; 15(34): 3895-3907, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31621403
4.
Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.
Future Oncol
; 15(29): 3381-3393, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31544510
5.
Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer.
Future Oncol
; 15(25): 2943-2953, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31037966
6.
The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Am J Perinatol
; 35(2): 192-200, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28881376
7.
Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US.
J Med Econ
; 24(1): 328-338, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33576296
8.
EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.
Cancer Treat Res Commun
; 27: 100327, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549984
9.
Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Adv Ther
; 37(2): 946-954, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31955357
10.
Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis.
Orphanet J Rare Dis
; 15(1): 47, 2020 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32054500
11.
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Lung Cancer
; 138: 131-138, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31733614
12.
Impact of Respiratory Syncytial Virus-Confirmed Hospitalizations on Caregivers of US Preterm Infants.
Clin Pediatr (Phila)
; 58(8): 837-850, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31007050
13.
Real-world outcomes in patients with unresected stage III non-small cell lung cancer.
Med Oncol
; 36(3): 24, 2019 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706218
14.
Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
J Med Econ
; 21(2): 192-200, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29041833
15.
Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
Clin Lung Cancer
; 19(4): 360-370, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29576407
16.
Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.
Infect Dis Ther
; 7(1): 121-134, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29149439
17.
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.
Infect Dis Ther
; 6(4): 477-486, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28866800
Resultados
1 -
17
de 17
1
Próxima >
>>